


L1 HAS NO ANSWERS  
L1 STR



REP G1=(0-1) CH  
REP G2=(0-2) CH  
NODE ATTRIBUTES:  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RSPEC 14 1 8  
NUMBER OF NODES IS 19

STEREO ATTRIBUTES: NONE


=> d his 13

(FILE 'REGISTRY' ENTERED AT 15:14:06 ON 16 APR 2008)

L3 597 S L1 FUL

=> d 14

L4 HAS NO ANSWERS  
L4 STR



REP G1=(0-1) CH  
REP G2=(0-2) CH  
NODE ATTRIBUTES:  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RSPEC 14 1 8  
NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE

=> search 14

ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:sss  
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:subset

ENTER SUBSET L# OR (END):ful  
 FUL IS NOT A VALID L#  
 L-numbers must be in the range L1-L999.  
 ENTER SUBSET L# OR (END):l3  
 ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):ful  
 FULL SUBSET SEARCH INITIATED 15:18:54 FILE 'REGISTRY'  
 FULL SUBSET SCREEN SEARCH COMPLETED - 597 TO ITERATE


100.0% PROCESSED 597 ITERATIONS 466 ANSWERS  
 SEARCH TIME: 00.00.01

L5 466 SEA SUB=L3 SSS FUL L4

=> d scan

L5 466 ANSWERS REGISTRY COPYRIGHT 2008 ACS ON STN  
 IN 3(2H)-Pyridazinone, 6-[(3S,4S)-3-(5-chloro-2-pyridinyl)-4-[(3R,5S)-4-hydroxy-3,5-dimethyl-4-phenyl-1-piperidinyl]carbonyl]-1-pyrrolidinyl]-  
 MF C27 H30 Cl N5 O3

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	224.14	224.35

FILE 'CAPLUS' ENTERED AT 15:19:26 ON 16 APR 2008  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Apr 2008 VOL 148 ISS 16  
FILE LAST UPDATED: 15 Apr 2008 (20080415/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l5

L6 15 L5

=> d bib abs 1-15

L6 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:966651 CAPLUS

DN 147:322997

TI Preparation of piperidinoylazinylpyrrolidines as melanocortin type 4 receptor agonists

IN Andrews, Mark David; Brown, Alan Daniel; Lansdell, Mark Ian; Summerhill, Nicholas William

PA Pfizer Limited, UK

SO PCT Int. Appl., 71pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007096763	A2	20070830	WO 2007-IB456	20070219
	WO 2007096763	A3	20071018		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
PRAI	US 2006-776295P	P	20060223		
	US 2007-887840P	P	20070202		
OS	MARPAT 147:322997				
GI					



AB Title compds. [I; 1 of X, Y = N, the other = CH; R = F, Cl, cyano, CF<sub>3</sub>, MeO; R<sub>1</sub> = (substituted) Ph, 2-pyridyl, cycloalkyl, cycloalkylmethyl; R<sub>2</sub> = H, F, Cl; Het = (substituted) 6-membered (aromatic) ring containing 1-2 N atoms;

with provisos], were prepared Thus, 2-chloro-5-cyanopyridine, (3R,4R,5S)-1-[[[(3S,4S)-4-(5-chloropyridin-2-yl)pyrrolidin-3-yl]carbonyl]-4-(4-fluorophenyl)-3,5-dimethylpiperidin-4-ol (preparation given), and ethyldiisopropylamine were heated together in MeCN at 70° overnight to give 77% 6-[(3S,4S)-3-(5-chloropyridin-2-yl)-4-[[[(3R,4R,5S)-4-(4-fluorophenyl)-4-hydroxy-3,5-dimethylpiperidin-1-yl]carbonyl]pyrrolidin-1-yl]nicotinonitrile. The latter showed MC<sub>4</sub> agonist activity with EC<sub>50</sub> <0.52 nM.

L6 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:150961 CAPLUS

DN 146:229190

TI Preparation of pyrrolidinylcarbonylpiperidines as melanocortin subtype 4 (MC<sub>4</sub>) receptor agonists for treatment of lower urinary tract dysfunction.

IN McMurray, Gordon; Phillips, Stephen Charles; Westbrook, Simon Lempriere

PA Pfizer Limited, UK

SO PCT Int. Appl., 85pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007015157	A2	20070208	WO 2006-IB2119	20060720
	WO 2007015157	A3	20070518		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TM, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	CA 2615209	A1	20070208	CA 2006-2615209	20060720
FRAI	GB 2005-15817	A	20050801		
	US 2005-705237P	P	20050802		
	WO 2006-IB2119	W	20060720		
OS	MARPAT 146:229190				
GI					



I

II

AB Use of MC4 receptor antagonists, e.g. [I; R1 = (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, etc.; R2 = H, OH, OMe; R3 = H, R1; R4, R5 = H, halo, alkyl, alkenyl, alkynyl, cyano, CF3, CH2CF3, OCF3, OCH2CF3, cycloalkenyl(alkyl), amino(alkyl), etc.; R4R5 = atoms to form fused 5-7 membered (unsatd.) ring] for the manufacture of a medicament for the treatment of lower urinary tract dysfunction is claimed. Thus, title compound (II) (preparation outlined) at 2 mg/kg i.v. in the dog urethral pressure model gave a 20% increase in peak urethral pressure.

L6 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:150182 CAPLUS

DN 146:229186

TI Preparation of piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds as MCR4 agonists

IN Andrews, Mark David; Brown, Alan Daniel; Fradet, David Sebastien; Lansdell, Mark Ian

PA Pfizer Limited, UK

SO PCT Int. Appl., 103pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007015162	A1	20070208	WO 2006-IB2151	20060726
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

FRAI US 2005-706191P P 20050804

OS MARPAT 146:229186

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [n = 1, 2; R6 = H, alkyl, cycloalkyl, etc.; R7 = pyridinyl or Ph (wherein pyridinyl or Ph is optionally substituted by halo, CN, CF3, etc.); R10 = Q1; R1, R4 = H, alkyl, OH, etc.; R2 = H, OH, O-alkyl, etc.; R3 = aryl or heteroaryl (wherein said moieties are optionally substituted by halo, CN, CF3, etc.); R5 = H or alkyl; R1, R4 and R5 are not all simultaneously H.; when R1 is Me and R4 is H, then R5 is not Me.; when R4 is Me and R5 is H, then R1 is not Me.; when R5 is Me and R4 is H, then R1 is not Me.], pharmaceutically acceptable salts, hydrates, solvates, polymorphs, and prodrugs thereof were prepared For example, amidation of (3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-carboxylic acid hydrochloride, e.g., prepared from (E)-2,4-difluorocinnamic acid in 3 steps, with (3S,4R)-3-methyl-4-phenylpiperidin-4-ol followed by treatment with HCl afforded compound II·HCl. Compds. according to the invention herein exhibited a binding constant at the MCR4 (melanocortin receptor 4) expressed as an Ki value against AGRP (agouti related protein) lower than 1000 nM. Compds. I are claimed useful for the treatment of sexual dysfunction and obesity.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:14419 CAPLUS

DN 146:121832

TI Preparation of pyrrolidinylcarbonylpiperidine derivative as MC4R agonist and of crystalline forms of said derivative

IN Calabria, Ralph; Cheng, Yu; Ferlita, Russell R.; Kamali, Ashkan; Murry, Jerry A.; Mathre, David; Peresypkin, Andrey V.; Thompson, Karen; Wang, Jian; Wenslow, Robert M.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 50pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007002462	A2	20070104	WO 2006-US24573	20060623
	WO 2007002462	A3	20070614		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

PRAI US 2005-694488P P 20050627

GI



II



III

AB The present invention relates to a process for producing N-((1S)-1-[2-(1-((1S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl)carbonyl)piperidin-4-yl]-5-chlorophenyl)ethyl)acetamide (I), and novel crystalline salts, hydrates, solvates, and polymorphic forms thereof. Thus, treatment of pyrrolidinecarboxylic acid II with CDI in acetonitrile, followed by reaction with piperidine derivative III in acetonitrile in the presence of triethylamine gave, after workup, I (free base). A solution of I (free base) in iso-Pr acetate was mixed with 0.5 N HCl/H<sub>2</sub>O solution to give, after workup and crystallization, the crystalline hydrate mono-HCl salt of I.

L6 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2006:1256650 CAPLUS  
 DN 146:33047  
 TI Combination therapy for the treatment of obesity  
 IN Macneil, Tanya; Macneil, Douglas J.  
 PA USA  
 SO U.S. Pat. Appl. Publ., 21pp.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20060270650	A1	20061130	US 2006-429721	20060508
PRAI	US 2005-684704P	P	20050526		

AB The present invention relates to compns. comprising calcium and/or xanthan gum and an anti-obesity agent, useful for the treatment and prevention of diabetes, obesity and obesity-related disorders. The present invention further relates to methods of treating or preventing obesity and obesity-related disorder in a subject in need thereof by administering a composition of the present invention. The present invention further provides for pharmaceutical compns., medicaments, and kits useful in carrying out these methods.

L6 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2006:365172 CAPLUS  
 DN 144:382018  
 TI Methods for the treatment of substance abuse and addiction  
 IN Bristow, Linda; Fong, Tung M.; Morse, Andrew C.  
 PA Merck & Co., Inc., USA  
 SO PCT Int. Appl., 63 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	WO 2006041769	A2	20060420	WO 2005-US35449	20050930
	WO 2006041769	A3	20070614		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	EP 1804798	A2	20070711	EP 2005-812168	20050930
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
	US 20080021067	A1	20080124	US 2007-662018	20070305
PRAI	US 2004-616064P	P	20041005		
	WO 2005-US35449	W	20050930		

OS MARPAT 144:382018

AB The present invention relates to methods of treating and preventing substance addiction and substance abuse, including nicotine addiction and nicotine addiction-related disorders in a subject comprising administering a melanocortin 4 receptor agonist to said subject. The present invention further relates to methods of treating or preventing substance addiction and substance addiction-related disorders in a subject comprising administering a melanocortin 4 receptor agonist to said subject. The present invention further provides for pharmaceutical compns. and medicaments useful in carrying out these methods.

L6 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2008 ACS ON STN

AN 2006:317218 CAPLUS

DN 144:363116

TI Combination therapy comprising PYY agonists for the treatment of obesity  
 IN Amatruda, John M.; Daruwala, Paul; Erondur, Ngozi E.; Macneil, Douglas J.; Moller, David E.; Qian, Su

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 99 pp.

CODEN: P1XXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006036770	A2	20060406	WO 2005-US34096	20050922
	WO 2006036770	A3	20060817		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2005289710	A1	20060406	AU 2005-289710	20050922



CA 2577821 A1 20060406 CA 2005-2577821 20050922  
 EP 1799241 A2 20070627 EP 2005-803387 20050922  
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR  
 CN 101027075 A 20070829 CN 2005-80032222 20050922  
 US 20080064632 A1 20080313 US 2007-661960 20070302  
 IN 2007CN01330 A 20070831 IN 2007-CN1330 20070330  
 PRAI US 2004-612657P P 20040924  
 WO 2005-US34096 W 20050922  
 OS MARPAT 144:363116  
 GI



AB The present invention relates to compns. comprising PYY, PYY3-36, or a PYY agonist, and an anti-obesity agent, useful for the treatment and prevention of obesity and obesity-related disorders. The present invention further relates to methods of treating or preventing obesity and obesity-related disorder in a subject in need thereof by administering a composition of the present invention. One example is a in vivo study of the effect of PYY3-36 on 4 h and 16 h food intake and body weight gain in mice and another example is an in vivo study of the effect of the combination of PYY3-36 and CB-1 inverse agonist AM-251 (I) on food intake and body weight in mice.

L6 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:236714 CAPLUS

DN 144:287793

TI Inhibition of voluntary ethanol consumption with non-peptidyl melanocortin 4-receptor agonists

IN Bristow, Linda; Fong, Tung M.; Morse, Andrew C.; Ren, Kunkun

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 60 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006028631	A2	20060316	WO 2005-US28128	20050809
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,				

ZA, ZM, ZW  
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
 GM, KE, LS, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM  
 EP 1781283 A2 20070509 EP 2005-812403 20050809  
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,  
 BA, HR, MK, YU  
 US 20080085885 A1 20080410 US 2007-660117 20070212  
 PRAI US 2004-601486P P 20040813  
 WO 2005-US28128 W 20050809  
 OS MARPAT 144:287793  
 AB The present invention relates to methods of inhibiting or reducing  
 voluntary alc. consumption in a subject comprising administering a  
 non-peptidyl melanocortin 4 receptor agonist to said subject. The present  
 invention further relates to methods of treating or preventing alcoholism,  
 alc. abuse, and alc. related disorders in a subject comprising  
 administering a non-peptidyl melanocortin 4 receptor agonist to said  
 subject. The present invention further provides for pharmaceutical  
 compns. and medicaments useful in carrying out these methods.  
 L6 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2006:165649 CAPLUS  
 DN 144:232924  
 TI Preparation of piperidine derivatives as melanocortin-4 receptor agonists  
 IN Barakat, Khaled J.; Guo, Liangqin; Liu, Jian; Nargund, Ravi P.; Sebbat,  
 Iyassu K.; Ye, Zhixiong  
 PA Merck & Co., Inc., USA  
 SO PCT Int. Appl., '79 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1  

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006019787	A2	20060223	WO 2005-US24806	20050713
WO 2006019787	A3	20060914		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005275232	A1	20060223	AU 2005-275232	20050713
CA 2573714	A1	20060223	CA 2005-2573714	20050713
EP 1773347	A2	20070418	EP 2005-769526	20050713
CN 1984662	A	20070620	CN 2005-80024053	20050713
JP 2008506696	T	20080306	JP 2007-521596	20050713
IN 2006CN04795	A	20071005	IN 2006-CN4795	20061229
US 20080051430	A1	20080228	US 2007-632001	20070109
PRAI US 2004-588494P	P	20040716		
WO 2005-US24806	W	20050713		
OS MARPAT 144:232924				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The title piperidine derivs. I [wherein m = 0-2; n = 1-2; R1 and R2 = independently halo, CF3, CH3, and OMe; R3 and R4 = independently halo, CF3, CN, alkyl, alkoxy, etc.; R5 = OH, halo, alkyl, alkoxy, etc.], or pharmaceutically acceptable salts thereof were prepared as agonists of the human melanocortin-4 receptors (MCR-4). For example, II was prepared in a multi-step synthesis. The title compds. showed IC50 less than 10  $\mu$ M against MCR-4. Formulations with finely divided lactose as hard gelatin capsule have been described. The compds. are useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MCR-4, such as obesity, diabetes, male or female sexual dysfunction.

L6 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 2005:735328 CAPLUS

DN 143:211844

TI Preparation of Pyrrolidinyl(carbonyl) piperidines as melanocortin receptor 4 agonists for therapeutic use

IN Calabrese, Andrew Antony; Fradet, David Sebastien; Hepworth, David; Lansdell, Mark

PA Pfizer Inc, UK

SO U.S. Pat. Appl. Publ., 102 pp.

CODEN: USXXCO


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20050176772	A1	20050811	US 2005-51144	20050203
	AU 2005213538	A1	20050825	AU 2005-213538	20050126
	CA 2555800	A1	20050825	CA 2005-2555800	20050126
	WO 2005077935	A1	20050825	WO 2005-IB208	20050126
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1716135	A1	20061102	EP 2005-702363		20050126
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CN 1930146	A	20070314	CN 2005-80007573		20050126
BR 2005007435	A	20070703	BR 2005-7435		20050126
JP 2007534668	T	20071129	JP 2006-551945		20050126
JP 4031814	B2	20080109			
NL 1028193	A1	20050808	NL 2005-1028193		20050204
NL 1028193	C2	20060420			
IN 2006DN04212	A	20070622	IN 2006-DN4212		20060721
MX 2006PA08934	A	20061002	MX 2006-PA8934		20060804

	NO 2006003944	A	20061031	NO 2006-3944	20060904
PRAI	GB 2004-2492	A	20040204		
	US 2004-543950P	P	20040212		
	GB 2004-12417	A	20040603		
	US 2004-580209P	P	20040615		
	GB 2004-25530	A	20041119		
	US 2004-634916P	P	20041210		
	WO 2005-1B208	W	20050126		
OS	MARPAT 143:211844				
GI					




AB The present invention relates to a class of melanocortin MCR4 agonists of general formula (I) wherein R1, R2, R3, R4 and R5 are as defined below and especially to selective MCR4 agonist compds., to their use in medicine, to compns. containing them, to processes for their preparation and to intermediates

used in such processes. The variables for I are: R1 = optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, alkylcycloalkyl, aryl, alkylaryl, heterocycle, or alkylheterocycle; R2 is H, OH or OCH3; R3 = H, or optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, alkylcycloalkyl, aryl, alkylaryl, heterocycle, or alkylheterocycle; R4 = H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, halogen, (CH2)pOR6, (CH2)pNR7R8, CN, C(O)R6, C(O)OR6, C(O)NR7R8, (CH2)pNR7SO2R8, CF3, CH2CF3, OCF3 or OCH2CF3 wherein p=0, 1 or 2; R5 = alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, halogen, (CH2)pOR6, (CH2)pNR7R8, CN, C(O)R6, C(O)OR6, C(O)NR7R8, (CH2)pNR7SO2R8, CF3, CH2CF3, OCF3 or OCH2CF3 wherein p=0, 1 or 2; or R4 and R5 form a fused ring; R6, R7 and R8 = H, CH3 or CH2CH3. Compds. of the present invention are particularly suitable for treating female sexual dysfunction, male erectile dysfunction, obesity and diabetes.

L6 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 2005:99460 CAPLUS  
DN 142:197886  
TI Preparation of 4-aryl-1-(pyrrolidinylcarbonyl)piperidines as melanocortin-4 receptor agonists  
IN Sings, Heather; Ujjainwalla, Feroze  
PA Merck & Co., Inc., USA  
SO PCT Int. Appl., 113 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

PI WO 2005009950 A2 20050203 WO 2004-US22911 20040716  
 WO 2005009950 A3 20050602  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 AU 2004259717 A1 20050203 AU 2004-259717 20040716  
 CA 2532808 A1 20050203 CA 2004-2532808 20040716  
 EP 1648457 A2 20060426 EP 2004-778422 20040716  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK  
 CN 1826116 A 20060830 CN 2004-80021119 20040716  
 JP 2006528180 T 20061214 JP 2006-521142 20040716  
 US 20060128963 A1 20060615 US 2005-560290 20051212  
 IN 2006DN00517 A 20070810 IN 2006-DN517 20060131  
 PRAI US 2003-489313P P 20030722  
 WO 2004-US22911 W 20040716  
 OS CASREACT 142:197886; MARPAT 142:197886  
 GI



AB Title compds. [I; R1 = H, amidino, alkylimino, alkyl, (CH<sub>2</sub>)<sub>n</sub>Q; n = 0-3; Q = (substituted) amino, cycloalkyl, Ph, naphthyl, heteroaryl; R2 = (substituted) Ph, naphthyl, heteroaryl; R3 = H, alkyl, halo, CF<sub>3</sub>, CH<sub>2</sub>CF<sub>3</sub>, OCF<sub>3</sub>, OCH<sub>2</sub>CF<sub>3</sub>, NO<sub>2</sub>, OR<sub>6</sub>, (substituted) (CH<sub>2</sub>)<sub>n</sub>Q1; Q1 = Ph, naphthyl, heteroaryl, heterocycloalkyl, cycloalkyl, amino, aminocarbonyl, cyano, etc.; R4 = (substituted) (CH<sub>2</sub>)<sub>n</sub>Q3; Q3 = NR<sub>5</sub>NR<sub>5</sub>R<sub>6</sub>, NR<sub>5</sub>R<sub>9</sub>, NR<sub>5</sub>CO(CH<sub>2</sub>)<sub>n</sub>CR<sub>5</sub>[N(R<sub>5</sub>)<sub>2</sub>](CH<sub>2</sub>)<sub>n</sub>NR<sub>5</sub>R<sub>6</sub>, etc.; q = 0-4; R5 = H, (substituted) alkyl, alkylcarbonyl; R6 = R5, (CH<sub>2</sub>)<sub>n</sub>Q4; Q4 = (substituted) cycloalkyl, heterocycloalkyl, Ph, naphthyl, heteroaryl, bicycloalkyl; R9 = specified amino acid residue; Z = N, CR1; p = 1, 2; m = 0-2], were claimed. Representative I bound to melanocortin-4 receptors with EC<sub>50</sub> = 10 μM.

L6 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2004:80448 CAPLUS  
 DN 140:122817  
 TI NPY5 antagonist-antiobesity agent combination for the prevention and treatment of diabetes, obesity, and obesity-related disorders  
 IN Macneil, Douglas J.; McIntyre, James H.; Van Der Ploeg, Leonardus H. T.; Ishihara, Akane  
 PA Merck & Co., Inc., USA; Banyu Pharmaceutical Co., Ltd.  
 SO PCT Int. Appl., 134 pp.

CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004009015	A2	20040129	WO 2003-US22077	20030714
	WO 2004009015	A3	20040304		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2492225	A1	20040129	CA 2003-2492225	20030714
	AU 2003253925	A1	20040209	AU 2003-253925	20030714
	EP 1534074	A2	20050601	EP 2003-765587	20030714
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	JP 2005533849	T	20051110	JP 2004-523149	20030714
	US 20050288213	A1	20051229	US 2005-520566	20050107
PRAI	US 2002-396603P	P	20020718		
	US 2002-417999P	P	20021011		
	WO 2003-US22077	W	20030714		

OS MARPAT 140:122817

AB The invention discloses compns. comprising a NFY5 antagonist and an antiobesity agent, useful for the treatment and prevention of diabetes, obesity, and obesity-related disorders. The invention also discloses methods of treating or preventing obesity and obesity-related disorders in a subject in need thereof by administering a composition of the invention. The invention further discloses pharmaceutical compns., medicaments, and kits useful in carrying out the methods.

L6 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2003:737505 CAPLUS

DN 139:255308

TI Agouti-related protein as biomarker for efficacy of appetite suppressant drugs

IN Fong, Tung M.; Shen, Chun-Pyn; Van der Ploeg, Leonardus H. T.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003075742	A2	20030918	WO 2003-US6437	20030303
	WO 2003075742	A3	20040401		
	W:	CA, JP, US			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR			
	CA 2477614	A1	20030918	CA 2003-2477614	20030303
	EP 1483580	A2	20041208	EP 2003-711370	20030303
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK			
	US 20050169839	A1	20050804	US 2004-506577	20040902

PRAI US 2002-361806P P 20020305  
 WO 2003-US6437 W 20030303

AB The present invention relates to agouti-related protein (AGRP) as a biomarker for the efficacy of appetite suppressant drugs given to humans or other mammals for the treatment of obesity. It further relates to a novel method of determining the efficacy of a test compound given to a subject for

the treatment of obesity, wherein the test compound is an appetite suppressant which does not stimulate the release of serotonin. It also relates to a method for following the progress of a therapeutic regime designed to alleviate obesity and to a method for determining the appropriate dosage of an appetite suppressant given to a subject for the treatment of obesity. Plasma levels of AGRP in lean rats were measured by RIA after treatment with various appetite suppressants. AGRP plasma levels were reduced by AM251, a cannabinoid CB1 inverse agonist, and by sibutramine.

L6 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2002:675993 CAPLUS

DN 137:216874

TI Acylated piperidine derivatives, specifically 1-(pyrrolidinylcarbonyl)piperidines, 1-(piperidinylcarbonyl)piperidines, and analogs, as melanocortin-4 receptor agonists, and their pharmaceutical compositions and therapeutic uses

IN Ujjainwalla, Feroze; Chu, Lin; Goulet, Mark T.; Lee, Bonnie; Warner, Daniel; Wyvratt, Matthew J.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 112 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002068388	A2	20020906	WO 2002-US5724	20020225
	WO 2002068388	A3	20030313		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2439152	A1	20020906	CA 2002-2439152	20020225
	AU 2002258414	A1	20020912	AU 2002-258414	20020225
	EE 200300415	A	20031215	EE 2003-415	20020225
	EP 1383501	A2	20040128	EP 2002-728357	20020225
	EP 1383501	B1	20070404		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	HU 2003003376	A2	20040128	HU 2003-3376	20020225
	HU 2003003376	A3	20070828		
	JP 2004529105	T	20040924	JP 2002-567902	20020225
	NZ 527364	A	20041224	NZ 2002-527364	20020225
	CN 1633297	A	20050629	CN 2002-805674	20020225
	BR 2002007658	A	20051025	BR 2002-7658	20020225
	AT 358481	T	20070415	AT 2002-728357	20020225
	ES 2283550	T3	20071101	ES 2002-728357	20020225
	US 20030225060	A1	20031204	US 2003-356879	20030203
	US 6818658	B2	20041116		

	ZA	2003006160	A	20040721	ZA	2003-6160	20030808
	BG	108132	A	20041230	BG	2003-108132	20030825
	IN	2003CN01342	A	20051125	IN	2003-CN1342	20030826
	NO	2003003812	A	20031028	NO	2003-3812	20030827
	MX	2003PA07785	A	20031208	MX	2003-PA7785	20030827
	US	20040266821	A1	20041230	US	2004-894719	20040720
	IN	2007CN02320	A	20071012	IN	2007-CN2320	20070529
PRAI	US	2001-2/2258P	P	20010228			
	US	2001-300118P	P	20010622			
	WO	2002-US5724	W	20020225			
	US	2003-356897	A3	20030203			
	IN	2003-CN1342	A3	20030826			
OS	MARPAT	137:216874					
GI							

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*





AB Certain novel 4-substituted N-acylated piperidine derivs., specifically I, are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R) [wherein: p = 1 or 2; q = 0, 1, or 2; n = 0, 1, or 2; R1 = H, amidino, alkyliminoyl, (un)substituted alkyl, (CH2)n-G1 [G1 = (un)substituted cycloalkyl, Ph, naphthyl, or heteroaryl]; R2 = (un)substituted Ph, naphthyl, or heteroaryl; X = alkyl, (CH2)n-G2 [G2 = (un)substituted cycloalkyl, Ph, naphthyl, heteroaryl, heterocyclyl, cyano, CONH2, CO2H, OH, NH2, and various derivs.] where any of (CH2)n may also be substituted; including pharmaceutically acceptable salts]. They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction. Approx. 180 invention compds. I and approx. 25 intermediates were prepared. For instance, (2-bromo-5-chlorophenyl)acetic acid underwent a sequence of Me esterification, coupling with tert-Bu 4-[(trifluoromethyl)sulfonyloxy]-3,6-dihydropyridine-1(2H)-carboxylate via a boronate ester, removal of the BOC group, and amidation with (3S,4R)-1-(tert-butyl)-4-(2,4-difluorophenyl)pyrrolidine-3-carboxylic acid. The unsatd. amide-ester underwent hydrogenation, saponification of the ester, and amidation with MeNH2.HCl, to give title compound II. Representative compds. I bound to cloned human MC-4R in vitro with IC50 values generally below 2  $\mu$ M, and also acted as agonists toward cloned human MCR in a functional assay with EC50 values less than 1  $\mu$ M.

L6 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 1999:172595 CAPLUS  
 DN 130:223167  
 TI Preparation of piperidinylpyrrolidins as modulators of chemokine receptor activity  
 IN Budhu, Richard J.; Hale, Jeffrey J.; Holson, Edward; Lynch, Christopher; Maccoss, Malcolm; Mills, Sander G.; Berk, Scott C.; Willoughby, Christopher A.  
 PA Merck & Co., Inc., USA  
 SO PCT Int. Appl., 262 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----



PI	WO 9909984	A1	19990304	WO 1998-US17755	19980827
	W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2298813	A1	19990304	CA 1998-2298813	19980827
	AU 9892067	A	19990316	AU 1998-92067	19980827
	EP 1009405	A1	20000621	EP 1998-944548	19980827
	R:	AT, BE, CH, DE, SI, LT, LV, FI, RO	DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,		
	US 6166037	A	20001226	US 1998-141227	19980827
	JP 2001526178	T	20011218	JP 2000-507374	19980827
PRAI	US 1997-57743P	P	19970828		
	GB 1998-1009	A	19980116		
	WO 1998-US17755	W	19980827		
OS	MARPAT 130:223167				
GI					



AB Title modulators [I; R1 = CH2Ph, SO2Ph, CONHPh, H, CPh, (CH2)3Ph, 1-fluorene-carbonyl, etc.; R = OH, H, Ph, CF3, CH2Ph, etc.; n = 0-2; S = S, C; R2 = benzo[d]azepin-3-yl, 4-phenyl-perhydroazepin-1-yl, etc.], pharmaceutically acceptable salts thereof, individual diastereomers, and enantiomers thereof are prepared as modulators of chemokine receptor activity. 21X19 combinatorial library was mentioned using com. available 4-sulfamylbenzoyl polystyrene resin supported subunits (21 pools) of trifluoromethylsulfonyl chloride, arylsulfonyl(carbonyl) chlorides, and heterocyclic sulfonyl(carbonyl) chlorides. Thus, compound II was prepared from Me (Z)-cinnamate and N-(methoxymethyl)-N-(trimethylsilylmethyl)benzylamine via seven steps.

RE.CNT 1        THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d hitstr 13-15

L6 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN


IT 455956-46-4

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(melanocortin receptor 4 agonist, plasma AGRP levels in lean rats after  
treatment with; agouti-related protein as biomarker for efficacy of  
appetite suppressant drugs)

RN 455956-46-4 CAPLUS

CN Benzamide, 2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-  
pyrrolidinyl]carbonyl]-4-piperidinyl]-5-fluoro-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN


IT 455956-36-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic  
preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
(Preparation); RACT (Reactant or reagent); USES (Uses)  
(drug candidate; preparation of acylated piperidine derivs., particularly  
(pyrrolidinylcarbonyl)piperidines, (piperidinylcarbonyl)piperidines,  
and analogs, as melanocortin-4 receptor agonists)

RN 455956-36-2 CAPLUS

CN Benzeneacetic acid, 5-chloro-2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-  
dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-, methyl ester (CA  
INDEX NAME)

Absolute stereochemistry.



IT 455955-95-0P 455955-96-1P 455955-97-2P

455955-98-3P 455955-99-4P 455956-00-0P  
455956-01-1P 455956-02-2P 455956-03-3P  
455956-04-4P 455956-05-5P 455956-06-6P  
455956-07-7P 455956-08-8P 455956-09-9P  
455956-10-2P 455956-11-3P 455956-12-4P  
455956-13-5P 455956-14-6P 455956-15-7P  
455956-16-8P 455956-17-9P 455956-18-0P  
455956-19-1P 455956-20-4P 455956-21-5P  
455956-22-6P 455956-23-7P 455956-24-8P  
455956-25-9P 455956-26-0P 455956-27-1P  
455956-28-2P 455956-29-3P 455956-30-6P  
455956-31-7P 455956-32-8P 455956-33-9P  
455956-34-0P 455956-35-1P 455956-37-3P  
455956-38-4P 455956-39-5P 455956-40-8P  
455956-41-9P 455956-42-0P 455956-43-1P  
455956-44-2P 455956-45-3P 455956-46-4P  
455956-47-5P 455956-48-6P 455956-49-7P  
455956-50-0P 455956-51-1P 455956-52-2P  
455956-53-3P 455956-54-4P 455956-55-5P  
455956-56-6P 455956-57-7P 455956-58-8P  
455956-59-9P 455956-60-2P 455956-61-3P  
455956-62-4P 455956-63-5P 455956-64-6P  
455956-65-7P 455956-66-8P 455956-67-9P  
455956-68-0P 455956-69-1P 455956-70-4P  
455956-71-5P 455956-72-6P 455956-73-7P  
455956-74-8P 455956-75-9P 455956-76-0P  
455956-77-1P 455956-78-2P 455956-79-3P  
455956-80-6P 455956-81-7P 455956-82-8P  
455956-83-9P 455956-84-0P 455956-85-1P  
455956-86-2P 455956-87-3P 455956-88-4P  
455956-89-5P 455956-90-8P 455956-91-9P  
455956-92-0P 455956-93-1P 455956-94-2P  
455956-95-3P 455956-96-4P 455956-97-5P  
455956-98-6P 455956-99-7P 455957-00-3P  
455957-01-4P 455957-02-5P 455957-03-6P  
455957-04-7P 455957-05-8P 455957-06-9P  
455957-07-0P 455957-08-1P 455957-09-2P  
455957-10-5P 455957-11-6P 455957-12-7P  
455957-13-8P 455957-14-9P 455957-15-0P  
455957-16-1P 455957-17-2P 455957-18-3P  
455957-19-4P 455957-20-7P 455957-21-8P  
455957-22-9P 455957-23-0P 455957-24-1P  
455957-25-2P 455957-26-3P 455957-27-4P  
455957-28-5P 455957-29-6P 455957-30-9P  
455957-31-0P 455957-32-1P 455957-33-2P  
455957-34-3P 455957-35-4P 455957-36-5P  
455957-37-6P 455957-38-7P 455957-39-8P  
455957-40-1P 455957-41-2P 455957-42-3P  
455957-43-4P 455957-44-5P 455957-45-6P  
455957-46-7P 455957-47-8P 455957-48-9P  
455957-49-0P 455957-50-3P 455957-51-4P  
455957-52-5P 455957-53-6P 455957-54-7P  
455957-55-8P 455957-56-9P 455957-57-0P  
455957-58-1P 455957-59-2P 455957-60-5P  
455957-61-6P 455957-65-0P 455957-66-1P  
455957-67-2P 455957-68-3P 455957-69-4P  
455957-70-7P 455957-71-8P 457068-69-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)


(drug candidate; preparation of acylated piperidine derivs., particularly

(pyrrolidinylcarbonyl)piperidines, (piperidinylcarbonyl)piperidines,  
and analogs, as melanocortin-4 receptor agonists)

RN 455955-95-0 CAPLUS

CN Benzeneacetamide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455955-96-1 CAPLUS

CN Benzamide, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N,N-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455955-97-2 CAPLUS

CN Benzamide, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N,N-diethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455955-98-3 CAPLUS

CN Piperidine, 1-[[ (3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-[2-(1-pyrrolidinylcarbonyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455955-99-4 CAPLUS

CN Benzamide, 2-[1-[[ (3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-(1,1-dimethylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-00-0 CAPLUS

CN Piperidine, 1-[[ (3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-[2-(1-piperidinylcarbonyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-01-1 CAPLUS

CN Benzamide, 2-[1-[[ (3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-02-2 CAPLUS

CN Benzamide, 2-[1-[(3S, 4R)-4-(2, 4-difluorophenyl)-1-(1, 1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-N-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-03-3 CAPLUS

CN Benzamide, 2-[1-[(3S, 4R)-4-(2, 4-difluorophenyl)-1-(1, 1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-N-propyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-04-4 CAPLUS

CN Piperidine, 4-[2-(1-azetidiny carbonyl)phenyl]-1-[(3S, 4R)-4-(2, 4-difluorophenyl)-1-(1, 1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-05-5 CAPLUS

CN Benamide, 2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-06-6 CAPLUS

CN Piperidine, 4-(2-cyano-4-fluorophenyl)-1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-07-7 CAPLUS

CN Benamide, 5-chloro-2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-08-8 CAPLUS

CN Benzamide, 5-chloro-2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-09-9 CAPLUS

CN Benzeneacetic acid, 2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-10-2 CAPLUS

CN Benzeneacetamide, 2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.






RN 455956-11-3 CAPLUS

CN Benzeneacetamide, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N,N-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-12-4 CAPLUS

CN Benzeneacetamide, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-13-5 CAPLUS

CN Benzeneacetamide, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-14-6 CAPLUS

CN Benzeneacetamide, N-cyclobutyl-2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidiny]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-15-7 CAPLUS

CN Piperidine, 4-[2-(1-azetidiny)-2-oxoethyl]phenyl]-1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-16-8 CAPLUS

CN Benzeneacetamide, 2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidiny]-N-(1,1-dimethylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-17-9 CAPLUS

CN Benzeneacetamide, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-ethyl-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-18-0 CAPLUS

CN Benzeneacetamide, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-methyl-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-19-1 CAPLUS


CN Benzeneacetamide, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N,N-diethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-20-4 CAPLUS  
 CN Piperidine, 1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-[2-[2-oxo-2-(1-pyrrolidinyl)ethyl]phenyl]- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-21-5 CAPLUS  
 CN Benzeneacetamide, 5-chloro-2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-ethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 455956-22-6 CAPLUS  
 CN Benzeneacetamide, 5-chloro-2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-propyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-23-7 CAPLUS

CN Benzeneacetamide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-24-8 CAPLUS

CN Benzeneacetamide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-(1,1-dimethylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-25-9 CAPLUS


CN Benzeneacetamide, 5-chloro-N-cyclopropyl-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-26-0 CAPLUS  
 CN Benzeneacetamide, 5-chloro-N-cyclobutyl-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-27-1 CAPLUS  
 CN Benzeneacetamide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N,N-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 455956-28-2 CAPLUS  
 CN Benzeneacetamide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N,N-diethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-29-3 CAPLUS

CN Benzeneacetamide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-ethyl-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-30-6 CAPLUS

CN Benzeneacetamide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-methyl-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-31-7 CAPLUS

CN Piperidine, 4-[2-[2-(1-azetidiny)-2-oxoethyl]-4-chlorophenyl]-1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-32-8 CAPLUS

CN Piperidine, 4-[4-chloro-2-[2-oxo-2-(1-pyrrolidinyl)ethyl]phenyl]-1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-33-9 CAPLUS

CN Piperidine, 4-[4-chloro-2-[2-oxo-2-(1-piperidinyl)ethyl]phenyl]-1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-34-0 CAPLUS

CN Benzeneacetamide, 5-chloro-2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-(1,1-dimethylethyl)-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.






RN 455956-35-1 CAPLUS

CN Benzoic acid, 5-chloro-2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-37-3 CAPLUS

CN Piperidine, 1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-[2-[(dimethylamino)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-38-4 CAPLUS

CN Benzamide, 2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-4-fluoro-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-39-5 CAPLUS

CN Benzoic acid, 2-[1-[[ (3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-6-methyl-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-40-8 CAPLUS

CN Benzamide, 2-[1-[[ (3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N,6-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-41-9 CAPLUS


CN Benzamide, 2-[1-[[ (3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N,N,6-trimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-42-0 CAPLUS  
 CN Benzoic acid, 2-[1-[[ (3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-methyl-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-43-1 CAPLUS  
 CN Benzamide, 2-[1-[[ (3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N,5-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 455956-44-2 CAPLUS  
 CN Benzoic acid, 5-chloro-2-[1-[[ (3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-45-3 CAPLUS

CN Benamide, 2-[1-[[[(3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N,4-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-46-4 CAPLUS

CN Benamide, 2-[1-[[[(3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-fluoro-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-47-5 CAPLUS


CN Benamide, 5-chloro-2-[1-[[[(3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N,N-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-48-6 CAPLUS  
 CN Benzamide, 5-chloro-2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-49-7 CAPLUS  
 CN Benzamide, 5-chloro-2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N,N-diethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 455956-50-0 CAPLUS  
 CN Benzamide, 5-chloro-2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-51-1 CAPLUS

CN Piperidine, 4-[2-(1-azetidinylicarbonyl)-4-chlorophenyl]-1-[[{(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-52-2 CAPLUS

CN Benzamide, 5-chloro-N-cyclopropyl-2-[1-[[{(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-53-3 CAPLUS

CN Benzamide, 2-[1-[[{(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-4,5-difluoro-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-54-4 CAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-fluorobenzoyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-55-5 CAPLUS


CN Benzamide, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-methyl-5-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 455956-56-6 CAPLUS  
 CN Piperidine, 4-[2-[2-(1-azetidiny)-1-methyl-2-oxoethyl]-4-chlorophenyl]-1-  
 [[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-  
 pyrrolidiny]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-57-7 CAPLUS  
 CN Piperidine, 4-[2-[2-(1-azetidiny)-1-methyl-2-oxoethyl]-4-chlorophenyl]-1-  
 [[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-  
 pyrrolidiny]carbonyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 455956-56-6  
 CMF C32 H40 Cl F2 N3 O2

Absolute stereochemistry.



CM 2




CRN 76-05-1  
CMF C2 H F3 O2




RN 455956-58-8 CAPLUS  
CN Benzeneacetamide, 5-chloro-2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N, $\alpha$ -dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-59-9 CAPLUS  
CN Benzeneacetamide, 5-chloro-2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-ethyl- $\alpha$ -methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-60-2 CAPLUS  
CN Benzeneacetamide, 5-chloro-2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]- $\alpha$ -methyl-N-propyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-61-3 CAPLUS  
 CN Benzeneacetamide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-α-methyl-N-(1-methylethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-62-4 CAPLUS  
 CN Benzeneacetamide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-(1,1-dimethylethyl)-α-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 455956-63-5 CAPLUS  
 CN Benzeneacetamide, 5-chloro-N-cyclopropyl-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-α-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-64-6 CAPLUS

CN Benzeneacetamide, 5-chloro-N-cyclobutyl-2-[1-[[ (3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-α-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-65-7 CAPLUS

CN Benzeneacetamide, 5-chloro-N-cyclopentyl-2-[1-[[ (3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-α-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-66-8 CAPLUS

CN Benzeneacetamide, 5-chloro-N-cyclohexyl-2-[1-[[ (3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-

piperidinyl]- $\alpha$ -methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-67-9 CAPLUS

CN Benzeneacetamide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N,N, $\alpha$ -trimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-68-0 CAPLUS

CN Benzeneacetamide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N,N-diethyl- $\alpha$ -methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-69-1 CAPLUS

CN Benzeneacetamide, 5-chloro-2-[1-[[ (3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-ethyl-N,α-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-70-4 CAPLUS

CN Benzeneacetamide, 5-chloro-2-[1-[[ (3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N,α-dimethyl-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-71-5 CAPLUS

CN Benzeneacetamide, 5-chloro-2-[1-[[ (3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-(1,1-dimethylethyl)-N,α-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-72-6 CAPLUS

CN Piperidine, 4-[4-chloro-2-[1-methyl-2-oxo-2-(1-pyrrolidinyl)ethyl]phenyl]-

1-[[ (3S, 4R)-4-(2, 4-difluorophenyl)-1-(1, 1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-73-7 CAPLUS

CN Piperidine, 4-[4-chloro-2-[1-methyl-2-oxo-2-(1-piperidinyl)ethyl]phenyl]-1-[[ (3S, 4R)-4-(2, 4-difluorophenyl)-1-(1, 1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-74-8 CAPLUS

CN 1-Propanone, 1-(1-azetidiny)-2-[5-chloro-2-[1-[[ (3S, 4R)-4-(2, 4-difluorophenyl)-1-(1, 1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-75-9 CAPLUS

CN Piperidine, 4-[2-[ (1R)-2-(1-azetidiny)-1-methyl-2-oxoethyl]-4-chlorophenyl]-1-[[ (3S, 4R)-4-(2, 4-difluorophenyl)-1-(1, 1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-76-0 CAPLUS

CN Benzeneacetic acid, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl- $\alpha,\alpha$ -dimethyl-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-77-1 CAPLUS

CN Benzeneacetic acid, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl- $\alpha,\alpha$ -dimethyl-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-78-2 CAPLUS

CN Benzeneacetamide, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl-N, $\alpha,\alpha$ -trimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-79-3 CAPLUS

CN Piperidine, 4-[2-[2-(1-azetidiny)-1,1-dimethyl-2-oxoethyl]-4-chlorophenyl]-1-[[ (3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidiny]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-80-6 CAPLUS

CN Piperidine, 4-[2-[2-(1-azetidiny)-1,1-dimethyl-2-oxoethyl]-4-fluorophenyl]-1-[[ (3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidiny]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-81-7 CAPLUS

CN Piperidine, 4-[2-[2-(1-azetidiny)-1,1-dimethyl-2-oxoethyl]phenyl]-1-[[ (3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidiny]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 455956-82-8 CAPLUS  
 CN Piperidine, 4-[2-[1-(1-azetidinylcarbonyl)cyclopropyl]-4-chlorophenyl]-1-  
 [[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-  
 pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 455956-83-9 CAPLUS  
 CN Cyclopropanecarboxamide, 1-[5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-  
 1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]-N-  
 methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-84-0 CAPLUS

CN Cyclopropanecarboxamide, 1-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-fluorophenyl]-N,N-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-85-1 CAPLUS

CN Piperidine, 4-[4-chloro-2-(1-hydroxy-1-methylethyl)phenyl]-1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 455956-86-2 CAPLUS

CN Benzeneacetamide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]- $\alpha,\alpha$ -dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-87-3 CAPLUS

CN Benzeneacetamide, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-4-fluoro-N, $\alpha,\alpha$ -trimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-88-4 CAPLUS

CN Benzeneacetamide, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-fluoro-N-(2-hydroxyethyl)-N, $\alpha,\alpha$ -trimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-89-5 CAPLUS

CN Morpholine, 4-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-fluorophenyl]-2-methyl-1-oxopropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-90-8 CAPLUS

CN Benzeneacetic acid, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-α,α-dimethyl-, hydrazide (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-91-9 CAPLUS

CN Benzeneacetic acid, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-α,α-dimethyl-, 2-(1-methylethyl)hydrazide (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-92-0 CAPLUS

CN Benzeneacetic acid, 5-chloro-2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-α,α-dimethyl-, 2-acetylhydrazide (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-93-1 CAPLUS

CN Acetamide, N-[[(1S)-1-[5-chloro-2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-94-2 CAPLUS

CN Piperidine, 4-(2-aminophenyl)-1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-95-3 CAPLUS

CN Acetamide, N-[2-[1-[(3S, 4R)-4-(2, 4-difluorophenyl)-1-(1, 1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-96-4 CAPLUS

CN Propanamide, N-[2-[1-[(3S, 4R)-4-(2, 4-difluorophenyl)-1-(1, 1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-97-5 CAPLUS

CN Propanamide, N-[2-[1-[(3S, 4R)-4-(2, 4-difluorophenyl)-1-(1, 1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-98-6 CAPLUS

CN Propanamide, N-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-99-7 CAPLUS

CN Cyclohexanecarboxamide, N-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-00-3 CAPLUS

CN Butanamide, N-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]-2-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-01-4 CAPLUS

CN Cyclopentanecarboxamide, N-[2-[1-[[ (3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-02-5 CAPLUS

CN Cyclohexanecarboxamide, N-[2-[1-[[ (3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 455957-03-6 CAPLUS

CN Benzamide, N-[2-[1-[[ (3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.






RN 455957-04-7 CAPLUS  
 CN Piperidine, 1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-[2-[(methylsulfonyl)amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 455957-05-8 CAPLUS  
 CN Piperidine, 4-[2-(aminomethyl)phenyl]-1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 455957-06-9 CAPLUS  
 CN Piperidine, 4-[2-[[[(diethylamino)carbonyl]amino]methyl]phenyl]-1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-07-0 CAPLUS

CN Piperidine, 1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-[2-[[[methyl(1-methylethyl)amino]carbonyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-08-1 CAPLUS

CN Piperidine, 1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-[2-[[[(methylamino)carbonyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-09-2 CAPLUS

CN Piperidine, 1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-[2-[[[(dimethylamino)carbonyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-10-5 CAPLUS

CN Piperidine, 1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-[2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-11-6 CAPLUS

CN Acetamide, N-[[2-[1-[[ (3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-12-7 CAPLUS

CN Propanamide, N-[[[2-[1-[[[3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-13-8 CAPLUS

CN Propanamide, N-[[2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]methyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-14-9 CAPLUS

CN Propanamide, N-[[2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]methyl]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-15-0 CAPLUS

CN Piperidine, 1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-[2-[(4,4-dimethyl-2-oxo-3-oxazolidinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-16-1 CAPLUS

CN Piperidine, 1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-[2-[(2-oxo-3-oxazolidinyl)methyl]phenyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 455957-17-2 CAPLUS

CN Piperidine, 1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-[2-[1-(2-oxo-3-oxazolidinyl)ethyl]phenyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 455957-18-3 CAPLUS

CN Piperidine, 1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-[2-[[[3,5-dimethyl-4-isoxazolyl]sulfonyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-19-4 CAPLUS

CN 1,2,5-Oxadiazole-3-carboxamide, N-[2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-20-7 CAPLUS

CN 1,2,5-Thiadiazole-3-carboxamide, N-[2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-21-8 CAPLUS

CN 4-Oxadiazolecarboxamide, N-[2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-22-9 CAPLUS

CN 5-Oxazolecarboxamide, N-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-23-0 CAPLUS

CN 1,3,4-Oxadiazole-2-carboxamide, N-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]-5-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-24-1 CAPLUS

CN 4-Isoxazolecarboxamide, N-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-25-2 CAPLUS

CN 1H-1,2,4-Triazole-3-carboxamide, N-[2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-26-3 CAPLUS

CN Piperidine, 4-[2-(1-aminoethyl)phenyl]-1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 455957-27-4 CAPLUS

CN Piperidine, 4-[2-(1-aminoethyl)-4-chlorophenyl]-1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 455957-28-5 CAPLUS

CN Acetamide, N-[1-[5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-29-6 CAPLUS

CN Acetamide, N-[1-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-fluorophenyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-30-9 CAPLUS

CN Acetamide, N-[(1R)-1-[5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-31-0 CAPLUS

CN Cyclobutanecarboxamide, N-[1-[5-chloro-2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-32-1 CAPLUS

CN Propanamide, N-[1-[5-chloro-2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-33-2 CAPLUS

CN Propanamide, N-[1-[5-chloro-2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]ethyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-34-3 CAPLUS

CN Propanamide, N-[1-[5-chloro-2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]ethyl]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-35-4 CAPLUS

CN Piperidine, 4-[4-chloro-2-[1-[(methylamino)carbonyl]amino]ethyl]phenyl]-1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-36-5 CAPLUS

CN Piperidine, 4-[4-chloro-2-[1-[[[(1,1-dimethylethyl)amino]carbonyl]amino]ethyl]phenyl]-1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-37-6 CAPLUS

CN Acetamide, N-[1-[2-[1-[[1-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-fluorophenyl]-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-38-7 CAPLUS

CN Acetamide, N-[1-[2-[1-[[1-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-39-8 CAPLUS

CN Piperidine, 4-[4-chloro-2-(5-oxo-3-pyrrolidinyl)phenyl]-1-[[1-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-40-1 CAPLUS

CN Piperidine, 4-[4-chloro-2-(5-oxo-2-pyrrolidinyl)phenyl]-1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-41-2 CAPLUS

CN Acetamide, N-[1-[2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-fluorophenyl]ethyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-42-3 CAPLUS

CN Acetamide, N-[1-[2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-43-4 CAPLUS

CN Acetamide, N-[(1S)-1-[5-chloro-2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]propyl]-(CA INDEX NAME)]


Absolute stereochemistry.



RN 455957-44-5 CAPLUS

CN Acetamide, N-[(1S)-1-[2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-ethylphenyl]ethyl]-(CA INDEX NAME)]


Absolute stereochemistry.



RN 455957-45-6 CAPLUS

CN Piperidine, 4-[2-[(1S)-1-aminoethyl]-4-chlorophenyl]-1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-(9CI) (CA INDEX NAME)]


Absolute stereochemistry.



RN 455957-46-7 CAPLUS

CN 1,3,4-Oxadiazole-2-carboxamide, N-[(1S)-1-[5-chloro-2-[1-[[ (3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]ethyl]-5-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-47-8 CAPLUS

CN 5-Thiazolecarboxamide, N-[(1S)-1-[5-chloro-2-[1-[[ (3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]ethyl]-1-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-48-9 CAPLUS

CN 1H-Imidazole-2-carboxamide, N-[(1S)-1-[5-chloro-2-[1-[[ (3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]ethyl]-1-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-49-0 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[(1S)-1-[5-chloro-2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-50-3 CAPLUS

CN Acetamide, N-[(1S)-1-[5-chloro-2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]-2-methylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 455957-51-4 CAPLUS

CN Piperidine, 4-[4-chloro-2-[1-(methylamino)ethyl]phenyl]-1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 455957-52-5 CAPLUS

CN Piperidine, 4-[4-chloro-2-[(2S)-5-oxo-2-pyrrolidinyl]phenyl]-1-[[ (3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 455957-53-6 CAPLUS

CN Piperidine, 4-[4-chloro-2-[(2R)-5-oxo-2-pyrrolidinyl]phenyl]-1-[[ (3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 455957-54-7 CAPLUS

CN Piperidine, 4-[4-chloro-2-(2-oxo-5-oxazolidinyl)phenyl]-1-[[ (3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-55-8 CAPLUS

CN Piperidine, 4-[4-chloro-2-(6-oxo-2-piperidinyl)phenyl]-1-[[3-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-56-9 CAPLUS

CN Piperidine, 4-[4-chloro-2-[(3R)-2-oxo-3-pyrrolidinyl]phenyl]-1-[[3-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-57-0 CAPLUS

CN Piperidine, 4-[4-chloro-2-[(3S)-2-oxo-3-pyrrolidinyl]phenyl]-1-[[3-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-58-1 CAPLUS

CN Piperidine, 4-[4-chloro-2-[(4R)-2-oxo-4-oxazolidinyl]phenyl]-1-[[ (3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 455957-59-2 CAPLUS

CN Piperidine, 4-[4-chloro-2-[(4S)-2-oxo-4-oxazolidinyl]phenyl]-1-[[ (3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 455957-60-5 CAPLUS

CN Acetamide, N-[(1R)-1-[2-[1-[[ (3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-fluorophenyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-61-6 CAPLUS

CN Acetamide, N-[(1S)-1-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-fluorophenyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-65-0 CAPLUS

CN Benzamide, 5-chloro-2-[1-[(3R,4S)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-66-1 CAPLUS

CN Piperidine, 4-[2-[1-(1-azetidiny carbonyl)cyclopropyl]-4-fluorophenyl]-1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-67-2 CAPLUS

CN Acetamide, N-[1-[5-chloro-2-[1-[[ (3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-68-3 CAPLUS

CN Piperidine, 1-[[ (3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-[4-fluoro-2-[1-[[ (methylamino)carbonyl]amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-69-4 CAPLUS


CN Cyclobutanecarboxamide, N-[1-[2-[1-[[ (3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-fluorophenyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 455957-70-7 CAPLUS  
 CN Propanamide, N-[1-[2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-fluorophenyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 455957-71-8 CAPLUS  
 CN Acetamide, N-[1-(1S)-1-[5-chloro-2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 457068-69-8 CAPLUS  
 CN Bicyclo[2.2.1]heptane-2-carboxamide, N-[2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 455957-79-6P 455957-80-9P 455957-84-3P

455957-85-4P 455957-86-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of acylated piperidine derivs., particularly (pyrrolidinylcarbonyl)piperidines, (piperidinylcarbonyl)piperidines, and analogs, as melanocortin-4 receptor agonists)

RN 455957-79-6 CAPLUS

CN Benzeneacetic acid, 5-chloro-2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-1,2,3,6-tetrahydro-4-pyridinyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-80-9 CAPLUS

CN Benzeneacetic acid, 5-chloro-2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-84-3 CAPLUS

CN Benzeneacetic acid, 5-chloro-2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-1,2,3,6-tetrahydro-4-pyridinyl]-α-methyl-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-85-4 CAPLUS

CN Benzeneacetic acid, 5-chloro-2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-α-methyl-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 455957-86-5 CAPLUS

CN Benzeneacetic acid, 5-chloro-2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-α-methyl-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.





L6 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN


IT 221142-59-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(preparation of piperidinylpyrrolidins as modulators of chemokine receptor activity)

RN 221142-59-2 CAPLUS

CN Piperidine, 4-phenyl-1-[[{(3R,4S)-4-phenyl-1-(phenylmethyl)-3-pyrrolidinyl]carbonyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 221141-75-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of piperidinylpyrrolidins as modulators of chemokine receptor activity)

RN 221141-75-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-phenyl-3-[(4-phenyl-1-piperidinyl)carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

